Evidence map›Paper›PMID 41744016›Full record

ArticleIntractable & rare diseases research2026

Medical security for rare disease patients in China: Insights from patients with Dravet syndrome.

Jingjing Wu, Xinyan Lu, Lei Gu, Yufei Yang, Miaomiao Zhang, Huimin Zhou, Linjie Zhou, Yafei Lan, Jun Li, Ningying Mao

Abstract read
In one paragraph

Article in Intractable & rare diseases research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingjing WuSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Xinyan LuSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Lei GuSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Yufei YangSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Miaomiao ZhangSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Huimin ZhouSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Linjie ZhouSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Yafei LanSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Jun LiSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Ningying MaoSchool of International Medicine Business, China Pharmaceutical University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high costs of diagnosing and treating rare diseases impose a substantial financial burden on patients and families, underscoring the need to understand reimbursement experiences and unmet needs to improve medical security. Using Dravet syndrome, a severe and lifelong epileptic encephalopathy, as a representative rare disease, this study conducted an online questionnaire survey completed by 161 respondents, including family members or caregivers of patients with Dravet syndrome. The results revealed that most families had insufficient income to cover treatment costs, with patients' annual treatment expenses generally approaching or even exceeding their families' financial capacity, while 41.67% reported that out-of-pocket payments after reimbursement accounted for more than half of their total treatment expense. Surveyed respondents expressed general satisfaction with various medical security models (over 75%), including basic medical insurance, critical illness insurance, medical assistance, commercial health insurance, and charitable aid. However, challenges remain: the limited funding pool and reimbursement capacity of basic medical insurance, the ongoing development of commercial insurance products (

Indexed as

ChinaDravet syndromemulti-tiered medical securitypolicy recommendationsrare diseases

Identifiers

PMID41744016
PMCPMC12932011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.